Vergelijking
Dulaglutide vs. Retatrutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
923950-08-7
2381089-83-2
Molecuulmassa
59670 g/mol
4731.6 g/mol
Halfwaardetijd
110 h
144 h
Sequentie
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSWerkingsmechanisme
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
5
waarvan bij mensen
5
4
Geregistreerde effecten
3
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
2
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Dulaglutide and Retatrutide?
- Dulaglutide is classified as "Metabool", while Retatrutide is classified as "Metabool". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Retatrutide?
- The highest available evidence level is "Humane RCT" for Dulaglutide and "Humane RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Retatrutide in Germany and the United States?
- Duitsland: Dulaglutide — Op recept, Retatrutide — Niet goedgekeurd. Verenigde Staten: Dulaglutide — Op recept, Retatrutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.